

Legal Division  
Pfizer Inc  
235 East 42nd Street  
New York, NY 10017  
Tel 212 733 3993 Fax 646 563 9655  
Email marguerite.sells@pfizer.com

---



**Marguerite Sells**  
Chief Counsel, Worldwide Pharmaceutical Operations  
Senior Vice President and Associate General Counsel

March 7, 2008

The Honorable Charles E. Grassley  
Ranking Member  
Senate Finance Committee  
SD-219 Dirksen Senate Office Building  
Washington, DC 20510-6200

Dear Senator Grassley:

We are in receipt of your February 26, 2008 letter to Jeffrey Kindler requesting information from Pfizer Inc ("Pfizer") regarding steps we have taken and are planning to take to enhance the transparency of our financial relationships with organizations such as patient groups and medical societies. We appreciate the opportunity to tell you about our efforts in this area, and look forward to working with you toward a shared goal of improved public health.

As we stated in our December 7, 2007 letter to you, in April 2007, Pfizer's Medical Education Policy Committee recommended the adoption of principles on disclosure of educational grants and other support for medical and patient organizations in the United States. We publicly announced our commitment to these principles on our website in June 2007 as follows:

*Consistent with our commitment to openness and transparency, Pfizer intends to report its medical educational grants and support for medical and patient organizations in the United States, beginning in 2008. Pfizer partners with many stakeholders and is working to make sure their views are included as the reporting process is developed and finalized.*

The website is located at  
[http://pfizer.com/responsibility/values\\_commitments/values\\_and\\_commitments.jsp](http://pfizer.com/responsibility/values_commitments/values_and_commitments.jsp)<sup>1</sup>.

---

<sup>1</sup> Pfizer Sales and Marketing personnel were entirely removed from the processing and evaluation of requests for educational grants to support events taking place after January 1, 2006. The Medical Education Group (MEG), a group within Pfizer's US Medical organization, has oversight responsibility and decision-making authority under this process.

**CONFIDENTIAL**

In December 2007, Pfizer followed up on this initial commitment with its Transparency Policy, which is posted on our Medical Education Grants website as follows:

*In 2008, Pfizer will begin reporting medical educational grants and other financial support provided to medical and patient organizations in the US. Pfizer's support for medical and patient organizations is one way we contribute to the improvement of patients' lives in conjunction with our core business of developing innovative medicines.*

*These plans reflect our commitment to increasing transparency around the funding Pfizer provides in support of organizations that work to improve the health of patients. In the past we've often shared this kind of information with individual organizations and in company communications. Now, with growing interest in broader information across the healthcare spectrum, public reporting is a natural next step.*

*To that end, such grants provided after January 1, 2008 will be given under the condition that the recipient consents to public disclosure. Details disclosed may include but are not limited to the recipient organization's name, the purpose for which the grant was given, and the amount of the grant.*

The website is located at

<https://www.pfizermededgrants.com/pfizercme/TransparencyPolicy.aspx>.

Further to those public announcements, in January of this year, Pfizer distributed letters to over 600 organizations potentially impacted by the Transparency Policy, formally notifying them of Pfizer's commitment to openness and transparency. A copy of that letter is attached.

It is Pfizer's plan to disclose medical education grants and other financial support to medical and patient organizations in the United States on a quarterly basis, beginning with information for the first quarter of 2008 (January 1 – March 31, 2008). Data from that period will be collected over several weeks after the close of the financial books in April, and will be posted on our website on or before May 15, 2008. Data from each subsequent quarter will be posted in a similar manner. Examples of support to be disclosed include: medical education grants, charitable contributions, and awards of fellowships and scholarships.


As you know, Pfizer and other pharmaceutical companies support many external medical organizations, including patient groups and medical societies. Such organizations carry out valuable work to improve the lives of patients with particular diseases or medical conditions, and they often look to industry for partnership and/or the provision of financial support and other resources for their activities. Pfizer's support for these organizations is one way we contribute to the improvement of patients' lives beyond our core business of developing innovative medicines.

**CONFIDENTIAL**

Again, thank you for your interest in Pfizer's commitment to transparency in its interactions with medical organizations.

Please feel free to contact Anthony Principi or Dolly Judge in our Washington office at 202.783.7070 if you have questions or require additional information.

Sincerely,

A handwritten signature in cursive script that reads "Marguerite Sells". The signature is written in black ink and is positioned above the printed name.

Marguerite Sells  
Chief Counsel, Worldwide Pharmaceutical Operations  
Senior Vice President & Associate General Counsel

**CONFIDENTIAL**

## TEMPLATE LETTER TO MEDICAL ORGANIZATIONS

January 2, 2008

Dear \_\_\_\_\_,

We are writing to you today to solicit your feedback on Pfizer's intention to publicly disclose funding in the U.S. for medical education grants and other grants to medical and patient organizations in 2008. As you know, Pfizer's support for these organizations – including yours – is one way we contribute to the improvement of patients' lives in conjunction with our core business of developing innovative medicines

These plans reflect our commitment to increasing transparency around the funding Pfizer provides in support of organizations like yours that work to improve the health of patients. In the past we've often shared this kind of information with individual organizations and in company communications. Now, with growing interest in broader information across the healthcare spectrum, public reporting is a natural next step.

To that end, such grants provided after January 1, 2008 will be given under the condition that the recipient consents to public disclosure. Details disclosed may include the recipient organization's name, the purpose for which the grant was given, and the amount of the grant.

**We want to emphasize how important we believe it is that your input be incorporated as this project evolves. As such, we ask that you send any comments you have, including any best practices you'd like to share, to the following e-mail address: [Transparency@Pfizer.com](mailto:Transparency@Pfizer.com) no later than January 31.**

Regards,

Cathryn Clary  
Vice President, US External Medical Affairs

Nina Hill  
Vice President, Worldwide Alliance  
Development

**CONFIDENTIAL**